Clostridium difficile DNA vaccine
The invention relates to compositions and methods for treating C. difficile associated disease (CDAD) through the administration to a subject in need thereof at least one nucleic acid encoding at least a portion of at least one of toxin A and toxin B.
1. A vaccine comprising at least one nucleic acid selected from the group consisting of:
a. a nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:3; and
b. a nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:4.
2. The vaccine of claim 1 , further comprising a nucleic acid encoding a secretory leader peptide.
3. The vaccine of claim 2 , wherein the secretory leader peptide is an IgE secretory leader peptide.
4. The vaccine of claim 1 , wherein the nucleic acid is incorporated into one expression vector.
5. The vaccine of claim 1 , wherein the nucleic acid is incorporated into two or more expression vectors.
6. The vaccine of claim 1 , wherein the at least one nucleic acid is codon-optimized for expression in a human cell.
7. An isolated nucleic acid encoding the amino acid sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.
8. A composition comprising an isolated nucleic acid encoding the amino acid sequence of SEQ ID NO:3 and an isolated nucleic acid encoding the amino acid sequence of SEQ ID NO:4.